Clinical trial registry record

Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 4 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated September 17, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT02246829
Last registry update
September 17, 2026
Status
Completed
Phase
Phase 4
Sponsor
University Hospital, Bordeaux
Enrollment
50
Countries
France
Match confidence
62%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 4
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
50
Population
ALL · 50 Years
Duration
2014-09-01 to 2015-06-01
Intervention
Intravitreal injection
Comparator
Not reported
Outcomes measured
Occurence of a Dry SD-OCT 12-week after initiation of a treatment by Aflibercept (EYLEA®) 2mg — 12-week after initiatio…; Time to get a dry SD-OCT after initiation of a treatment by Aflibercept — Every 2 weeks from treatment initiation (incl…; Evolution of morphological and visual modification under Aflibercept (EYLEA®) — Every 2 weeks from treatment initiation…; Occurence of pigment epithelial detachment — Every 2 weeks from treatment initiation (inclusion) to week 12; Evolution of retinal hemorrhage if any — Every 2 weeks from treatment initiation (inclusion) to week 12; Evolution in the atrophic lesions — Every 2 weeks from treatment initiation (inclusion) to week 12; Occurence the central Retinal Thickness — Every 2 weeks from treatment initiation (inclusion) to week 12
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 4A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 62% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 62%Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON